Sio Capital Management
MBRX icon

Sio Capital Management’s Moleculin Biotech MBRX Stock Holding History

Sio Capital Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-36
Closed -$116K – 48
2023
Q3 		$116K Sell
36
-4
-10% -$16.5K 0.04% 47
2023
Q2 		$176K Sell
40
-95
-70% -$501K 0.04% 40
2023
Q1 		$971K Sell
135
-3
-2% -$26.3K 0.48% 30
2022
Q4 		$1.1M Hold
138
– – 0.41% 32
2022
Q3 		$1.1M Hold
138
– – 0.35% 34
2022
Q2 		$1.5M Sell
138
-1
-0.7% -$11.6K 0.56% 36
2022
Q1 		$1.85M Hold
139
– – 0.61% 37
2021
Q4 		$1.94M Hold
139
– – 0.58% 42
2021
Q3 		$3.12M Buy
139
+5
+4% +$117K 1% 33
2021
Q2 		$3.69M Buy
134
+6
+5% +$164K 0.92% 39
2021
Q1 		$3.93M Buy
+128
New +$4.69M 0.8% 43

Other funds holding MBRX

Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Atticus Wealth Management
Atticus Wealth Management Palm Beach Gardens, Florida $452M AUM 17.19% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Sio Capital Management's MBRX Position: Q4 2023 in Review

Sio Capital Management sold out of Moleculin Biotech (MBRX) in Q4 2023, closing a stake of 36 shares — an estimated $116K sold.

Sio Capital Management first reported a position in MBRX in Q1 2021 and held it in 11 quarters. The position peaked at $3.93M in Q1 2021. 15 funds tracked by Wall St. Rank hold MBRX as of Q4 2023.

  • Sio Capital Management reported no remaining Moleculin Biotech position as of Q4 2023 after selling out during the quarter.
  • Sio Capital Management sold 36 Moleculin Biotech shares in Q4 2023, an estimated $116K.
  • Sio Capital Management first reported a position in Moleculin Biotech in Q1 2021 and held it in 11 quarters.
  • Sio Capital Management's Moleculin Biotech position peaked at $3.93M in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2023.

Based on Sio Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.